Oneview Healthcare (ASX: ONE) Retreats as Investors Assess Digital Health Growth Strategy

Aditi Sarkar

21 July 2026 02:24 PM AEST

Oneview Healthcare (ASX: ONE) Retreats as Investors Assess Digital Health Growth Strategy

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Oneview Healthcare (ASX: ONE) declined nearly 6% during intraday trading.
No confirmed company-specific announcement accompanied the move.
FY2025 revenue increased to approximately EUR12.0 million.
US expansion remains supported by strategic technology partnerships.

Oneview Healthcare PLC (ASX: ONE) traded lower during intraday trading on 21 July 2026 as investors continued navigating volatility across smaller healthcare technology companies. The decline occurred without any confirmed company-specific announcement, with the movement appearing against a backdrop of relatively thin trading volumes and broader market sentiment rather than a specific operational development. The reported decline represented an intraday trading snapshot rather than the official market close.

Digital Platform Focused on Hospital Care

Oneview Healthcare develops digital patient engagement technology designed for hospitals.

Its software platform connects bedside televisions, tablets, digital whiteboards and clinical systems to improve communication between patients, healthcare professionals and family members. The platform also supports patient education, meal ordering, entertainment, hospital information and integration with electronic medical records.

The company operates across hospitals in the United States, Australia, Ireland, the Middle East and Asia, with the United States representing its primary growth market. Revenue is increasingly generated through recurring software subscriptions linked to hospital deployments.

Revenue Continued to Expand During FY2025

For the financial year ended 2025, Oneview reported revenue of approximately EUR12.0 million, representing growth of around 21% compared with the previous year.

Recurring revenue increased to approximately EUR7.7 million as additional hospital deployments became operational. Customer receipts also improved during the fourth quarter, while operating cash outflows narrowed compared with earlier reporting periods.

The company finished 2025 with approximately 14,880 live endpoints operating across more than 80 hospitals globally. Growth in deployed endpoints remains an important performance indicator because it supports recurring subscription revenue over the life of customer contracts.

During March 2026, Oneview also completed an approximately AUD19 million capital raising to support future commercial expansion and ongoing product development.

Strategic Partnerships Continue Supporting Growth

Expansion across the United States remains central to Oneview's commercial strategy.

The company continues working with Baxter International, which supports sales and distribution of the platform across hospital networks. This relationship has broadened commercial opportunities through major healthcare purchasing organisations.

Oneview has also expanded its collaboration with Epic Systems through integration with MyChart Bedside, allowing hospitals to deliver patient services using existing electronic medical record systems.

Management continues focusing on converting a growing sales pipeline into live hospital deployments while increasing recurring software revenue across its installed customer base.

Commercial Execution Remains the Key Focus

Although the broader healthcare technology market continues offering long-term opportunities, successful execution remains essential.

Growth will largely depend on converting signed opportunities into operational hospital deployments and expanding recurring revenue through additional endpoints. As a relatively small technology company, Oneview also remains sensitive to trading liquidity, contributing to periods of elevated share-price volatility.

While no confirmed company-specific announcement explained the latest share-price weakness, investors continue monitoring commercial progress across the company's expanding hospital customer base.

What Investors May Watch Next

Investors are likely to monitor new hospital contract wins, endpoint growth, recurring revenue expansion, commercial progress within the United States, strategic partnerships with Baxter and Epic Systems, and future financial updates.

Risks

Oneview Healthcare remains exposed to customer adoption risk, extended hospital procurement cycles, funding requirements and commercial execution challenges. As a relatively small healthcare technology company, the shares may also experience higher volatility because of lower trading liquidity. Competition within digital healthcare technology and slower-than-expected deployment activity could also affect future performance.

FAQs

Q: Why did Oneview Healthcare shares decline?

A:No confirmed company-specific announcement accompanied the intraday decline, with broader market sentiment and lower trading liquidity appearing to influence the move.

Q: What does Oneview Healthcare do?

A:The company develops digital patient engagement software used by hospitals to improve bedside communication, patient services and integration with clinical systems.

Q: What were the company's latest financial highlights?

A:FY2025 revenue increased to approximately EUR12.0 million, while recurring revenue reached around EUR7.7 million across more than 80 hospitals.

Q: What developments may investors monitor next?

A:Investors may watch hospital contract wins, endpoint deployment growth, recurring revenue, US expansion and future company announcements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.